As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn in 2023; Pertussis prevention treatment approved for use during pregnancy.
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Rezlidhia is a small molecule inhibitor of mutated IDH1.